GlassScriptPhysician profile
Jami J Newman
NPI 1942368436
$1,108.41
in general payments reported to CMS, 2019-2025
17 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $90.20 · 2022: $12.76 · 2023: $229 · 2024: $128 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $325.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $134.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $125.28 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.33 | 2019-2020 | |
| Pfizer INC. | $75.80 | 2019-2025 | |
| Exact Sciences Corporation | $70.44 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $54.27 | 2019-2025 | Shingrix, Bexsero, Rotarix |
| Phadia US INC. | $44.06 | 2019-2025 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2024-2025 | Airsupra |
| Sanofi Pasteur INC. | $26.50 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $25.27 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.52 | 2025 | Rexulti |
| Amgen INC. | $17.97 | 2025 | Otezla, Repatha |
| Allergan, INC. | $17.50 | 2020 | |
| Hologic Sales and Service, LLC | $13.95 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.